Release Date: February 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Is the previous guidance for Stellar Blue's revenue of $120 to $150 million for 2025 still relevant? A: Yes, this guidance is still relevant and is included in the overall guidance. (Respondent: Unidentified_4)
Q: Will Stellar Blue be a separate segment in the new organizational structure? A: Stellar Blue is not a reportable segment. It is managed out of the commercial division with synergies between Gilat's IFC sub-segment and Stellar Blue. The results will be consolidated under the Gilat commercial division. (Respondent: Unidentified_3)
Q: What are the expected costs related to the new organizational structure? A: A presentation on the segment change is available on our website, providing high-level financial results for 2023 and 2024 to assist analysts and investors. (Respondent: Unidentified_3)
Q: Why is there a slight decrease in EBITDA margin in the 2025 guidance compared to 2024? A: Stellar Blue has a lower gross profit, affecting EBITDA. Stellar Blue is in its production ramp-up phase and is expected to be EBITDA positive by the second half of the year. Additionally, significant investments in the defense division, especially in R&D and sales and marketing, contribute to the lower EBITDA ratio for 2025. (Respondent: Unidentified_3)
Q: What is the expected timeline for contracts associated with the Iris Square Consortium? A: Initial discussions are positive. The consortium is expected to issue additional RFIs or RFPs by mid-2025, with awards anticipated before the end of the year and agreements signed in early 2026. However, this timeline may be aggressive, and delays are possible. (Respondent: Unidentified_3)
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.